NextBlue of North Dakota Medicare Advantage Important Message

NextBlue of North Dakota Medicare Advantage Plan would like to inform providers that two new part B drugs will require prior authorization as of July 22, 2024. The Federal Drug Administration (FDA) just approved HCPCS code J0175: Kisunla™ (donanemab-azbt) and HCPCS code J7699: Ohtuvayre™ (ensifentrine). These drugs will require prior approval effective on/after July 22, 2024.

The NextBlue Part B drug list will be updated shortly, which is located on the NextBlue Provider Website under Provider Resources | Prior Authorizations (nextbluend.com).

Questions?
Contact the NextBlue of North Dakota Provider Call Center at 1-844-753-8039.